Marshall Wace led Inquis Medical’s oversubscribed $40 million Series B round, along with participation from existing investors, including ShangBay Capital, Yu Star, EnPointe Ventures, and Pierre Lamond.
Inquis Medical is a clinical-stage medical device company dedicated to bringing a next-generation thrombectomy systems to market. Its flagship product, the Aventus Precision Thrombectomy System, features proprietary tissue-sensing technology that provides operators with real-time information on the tissue composition in contact with the device. This innovative system offers enhanced precision and control during procedures, pushing the boundaries of what current thrombectomy systems can achieve.
Earlier this year, Inquis received FDA 510(k) clearance for the tissue-sensing product, as well as its blood return system for peripheral indications, and is nearing completion of enrollment in an FDA Investigational Device Exemption (IDE) pivotal clinical study targeting pulmonary embolism (PE) patients. This capital injection represents a significant milestone in Inquis Medical’s rapid development and will enable the company to complete its pivotal IDE trial, prepare for the commercial launch of the Aventus Precision Thrombectomy System in 2025, and continue to advance its proprietary tissue-sensing platform.
The deal team was led by partner Jon O’Connell, with support from partners Anne Li and Debbie Yellin, counsel Justin Lurie, and associate Jonathan Camello.
